AXSM - Axsome Therapeutics Inc Stock Price, Fair Value and News

76.54-0.81 (-1.05%)Market Closed

Market Summary

76.54-0.81

Market Closed

-1.05%

AXSM Alerts

Big fall in Revenue (Y/Y)

Big fall in earnings (Y/Y)
Losses in recent quarter

AXSM Stock Price

View Fullscreen

AXSM RSI Chart

AXSM Valuation

Market Cap

3.6B

Price/Earnings (Trailing)

-12.28

Price/Sales (Trailing)

14.5

EV/EBITDA

-12.5

Price/Free Cashflow

-18.83

AXSM Price/Sales (Trailing)

AXSM Profitability

EBT Margin

-118.71%

Return on Equity

-205.77%

Return on Assets

-54.31%

Free Cashflow Yield

-5.31%

AXSM Fundamentals

AXSM Revenue

Revenue (TTM)

251.0M

Rev. Growth (Yr)

-20.7%

Rev. Growth (Qtr)

4.85%

AXSM Earnings

Earnings (TTM)

-296.4M

Earnings Growth (Yr)

-509.35%

Earnings Growth (Qtr)

30.71%

Breaking Down AXSM Revenue

Last 7 days

5.7%

Last 30 days

10.0%

Last 90 days

-17.4%

Trailing 12 Months

-0.3%

How does AXSM drawdown profile look like?

AXSM Financial Health

Current Ratio

3.2

Debt/Equity

1.24

Debt/Cashflow

-1.08

AXSM Investor Care

Shares Dilution (1Y)

9.00%

Diluted EPS (TTM)

-6.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	251.0M	0	0	0
2023	144.6M	182.5M	223.4M	270.6M
2022	0	0	0	50.0M
2021	0	0	0	0
2020	0	0	0	0
2019	0	0	287.1K	356.9K
2018	209.7K	212.3K	214.8K	217.4K
2017	0	0	0	207.1K
2016	1.8M	1.4M	914.0K	474.3K
2014	0	0	0	2.2M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Axsome Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	jacobson mark l.	acquired	32,060	1.3	24,662	chief operating officer
Apr 01, 2024	jacobson mark l.	sold	-1,904,940	77.242	-24,662	chief operating officer
Mar 15, 2024	jeffs roger	acquired	70,198	29.91	2,347	-
Mar 15, 2024	jeffs roger	sold	-168,062	71.6072	-2,347	-
Mar 14, 2024	jeffs roger	acquired	719,787	24.0121	29,976	-
Mar 14, 2024	jeffs roger	sold	-2,089,390	69.702	-29,976	-
Sep 15, 2023	coleman mark	sold	-1,396,190	75.1771	-18,572	-
Sep 15, 2023	coleman mark	sold	-828,241	75.1853	-11,016	-
Sep 15, 2023	coleman mark	acquired	40,428	3.67	11,016	-
Jan 03, 2023	coleman mark	acquired	22,751	1.3	17,501	-

Which funds bought or sold AXSM recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	new	-	6,131,590	6,131,590	0.16%
May 16, 2024	ALETHEA CAPITAL MANAGEMENT, LLC	reduced	-1.5	-740,060	59,115,100	48.02%
May 16, 2024	CASTLEARK MANAGEMENT LLC	new	-	2,569,560	2,569,560	0.11%
May 16, 2024	COMERICA BANK	added	7,716	714,267	723,487	-%
May 16, 2024	JANE STREET GROUP, LLC	added	114	8,498,080	15,886,500	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-5.85	-147,921	2,493,830	-%
May 15, 2024	Schonfeld Strategic Advisors LLC	reduced	-43.67	-3,701,030	4,802,520	0.03%
May 15, 2024	Altium Capital Management LP	unchanged	-	28,980	11,012,400	4.36%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	4,788	4,788	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	unchanged	-	28.00	10,773	-%

Are Funds Buying or Selling AXSM?

Are funds buying AXSM calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own AXSM

No. of Funds

Unveiling Axsome Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	fairmount funds management llc	4.9%	2,360,077	SC 13G/A
Feb 14, 2024	rtw investments, lp	9.5%	4,489,596	SC 13G/A
Feb 13, 2024	vanguard group inc	7.81%	3,696,766	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	3,239,746	SC 13G/A
Jul 07, 2023	fairmount funds management llc	5.0%	2,344,980	SC 13G
Feb 14, 2023	venrock healthcare capital partners ii, l.p.	0.0%	0	SC 13G/A
Feb 14, 2023	fairmount funds management llc	4.6%	2,011,647	SC 13G/A
Feb 14, 2023	rtw investments, lp	6.9%	2,980,482	SC 13G
Feb 14, 2023	pfm health sciences, lp	3.2%	6	SC 13G/A
Feb 09, 2023	vanguard group inc	7.87%	3,417,628	SC 13G/A

Recent SEC filings of Axsome Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 06, 2024	10-Q	Quarterly Report
May 06, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 01, 2024	144	Notice of Insider Sale Intent
Apr 01, 2024	4	Insider Trading
Apr 01, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 25, 2024	8-K	Current Report
Mar 19, 2024	8-K	Current Report

Peers (Alternatives to Axsome Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Axsome Therapeutics Inc News

Latest updates

Axsome Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q1	2019Q4	2019Q3	2018Q4	2018Q3	2018Q2	2018Q1
Revenue	4.8%	74,999,000	71,530,000	57,794,000	46,700,000	94,576,000	24,371,000	16,846,000	8,820,000	-	-	-	-	-	-	-	-	139,448	-	217,418	270,325	323,232
Costs and Expenses	-16.2%	142,274,000	169,804,000	119,914,000	111,757,000	100,950,000	84,288,500	59,258,000	48,001,000	38,289,000	32,608,110	33,407,142	30,847,687	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	38,288,872	32,608,040	33,407,142	30,847,687	27,844,061	27,744,236	32,491,457	24,428,170	18,947,235	9,450,315	8,243,459	7,989,593	7,163,210
S&GA Expenses	14.0%	98,970,000	86,809,000	83,188,000	78,935,000	74,191,000	61,498,000	40,892,000	31,160,000	25,704,000	18,826,383	20,226,884	16,344,361	11,248,372	10,359,507	4,970,057	5,222,899	3,111,662	2,299,083	2,202,679	2,439,061	-
R&D Expenses	19.6%	36,830,000	30,803,000	28,767,000	20,581,000	17,793,000	14,693,000	14,877,000	15,792,000	12,585,000	13,781,728	13,180,258	14,503,326	16,595,689	17,384,729	27,521,400	19,205,271	15,835,573	7,151,232	6,040,780	5,550,532	-
EBITDA Margin	-36.1%	-1.11	-0.82	-0.83	-0.93	-1.01	-3.58	-347	-351	-352	-352	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	0.7%	4,903,000	4,868,000	4,730,000	3,916,000	3,216,000	2,569,000	2,531,000	1,467,000	1,119,000	1,142,917	1,169,166	1,169,167	1,143,750	917,955	379,167	308,339	383,334	186,941	182,357	195,801	-
Income Taxes	100.0%	-	-335,000	-678,000	-617,000	2,600,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-217,418	-	-
Earnings Before Taxes	30.9%	-68,357,000	-98,976,000	-62,877,000	-67,787,000	-8,638,000	-61,241,000	-44,823,000	-41,438,000	-39,632,000	-	-	-	-	-	-	-	-	-	-	-	-
EBT Margin	-34.8%	-1.19	-0.88	-0.90	-1.00	-1.08	-3.74	-365	-365	-365	-365	-	-	-	-	-	-	-	-	-	-	-
Net Income	30.7%	-68,357,000	-98,651,000	-62,199,000	-67,170,000	-11,218,000	-61,240,500	-44,823,000	-41,439,000	-39,632,000	-33,976,144	-34,882,677	-32,284,209	-29,259,970	-29,164,647	-32,484,146	-24,806,984	-19,135,612	-9,597,015	-8,281,974	-8,280,916	-
Net Income Margin	-33.5%	-1.18	-0.88	-0.90	-1.01	-1.10	-3.74	-447	-420	-394	-365	-351	-318	-	-	-	-	-	-	-	-	-
Free Cashflow	-76.4%	-53,565,000	-30,369,000	-53,919,000	-55,482,000	-5,892,000	-27,744,000	-22,824,000	-33,778,000	-32,867,000	-28,841,206	-27,034,880	-25,412,430	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-7.2%	546	588	601	612	389	331	339	181	89.00	88.00	117	143	167	186	204	191	198	221	44.00	55.00	44.00
Current Assets	-8.7%	460	504	512	520	304	246	252	104	87.00	87.00	115	142	165	184	203	191	198	220	44.00	55.00	44.00
Cash Equivalents	-14.2%	331	386	417	437	247	201	228	73.00	85.00	86.00	115	141	165	184	202	191	197	220	44.00	54.00	43.00
Inventory	3.0%	16.00	15.00	10.00	9.00	8.00	4.00	2.00	10.00	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	-4.0%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	12.00	12.00	12.00	12.00	10.00	10.00	12.00	12.00	12.00	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	1.1%	402	397	331	333	277	222	182	165	74.00	72.00	74.00	72.00	71.00	72.00	68.00	37.00	42.00	42.00	38.00	30.00	27.00
Current Liabilities	3.7%	144	139	115	115	101	97.00	60.00	43.00	25.00	23.00	25.00	23.00	22.00	23.00	20.00	23.00	26.00	24.00	19.00	13.00	8.00
Long Term Debt	0.3%	179	178	177	177	148	94.00	94.00	93.00	49.00	49.00	49.00	49.00	49.00	48.00	48.00	14.00	16.00	17.00	19.00	17.00	19.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	7.00	5.00	3.00	1.00	2.00	1.00
LT Debt, Non Current	-100.0%	-	178	177	177	148	94.00	94.00	93.00	49.00	49.00	49.00	49.00	49.00	48.00	48.00	14.00	16.00	17.00	19.00	17.00	19.00
Shareholder's Equity	-24.6%	144	191	270	279	112	110	157	15.00	15.00	16.00	43.00	71.00	96.00	114	135	154	156	179	7.00	24.00	17.00
Retained Earnings	-8.2%	-903	-835	-736	-674	-607	-596	-535	-490	-448	-409	-375	-340	-308	-278	-249	-226	-208	-175	-151	-132	-118
Additional Paid-In Capital	2.1%	1,048	1,027	1,006	954	719	706	692	505	464	425	418	412	404	393	385	381	365	355	158	156	136
Shares Outstanding	0.2%	47.00	47.00	47.00	47.00	44.00	43.00	42.00	39.00	38.00	38.00	38.00	38.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	2,800	-	-	-	1,200	-	-	-	2,000	-	-	-	2,400	-	-	-	675	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-76.1%	-53,467	-30,362	-53,548	-55,349	-5,821	-27,563	-22,758	-33,537	-32,653	-28,840	-26,776	-25,393	-27,215	-20,553	-15,734	-18,895	-23,273	-17,567	-10,626	-8,681	-9,499
Share Based Compensation	6.7%	20,190	18,915	14,840	15,922	12,943	10,768	9,198	10,162	7,598	5,890	5,725	5,456	3,731	5,606	2,869	4,148	2,134	2,814	1,156	889	1,256
Cashflow From Investing	-1300.0%	-98.00	-7.00	-371	-133	-71.00	-181	-66.00	-53,241	-214	-451*	-258	-18.88	-29.99	-20.29	-14.84	-1.43	-9.33	-1.46	-3.20	-	-
Cashflow From Financing	-59250.0%	-1,187	-2.00	33,370	246,080	51,565	1,066	176,950	75,464	31,102	691	439	1,971	8,029	2,090	27,428	12,265	630	193,893	519	19,822	38,155

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

AXSM Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues [Abstract]
Revenue	$ 74,999	$ 94,576
Operating expenses:
Cost of revenue (excluding amortization and depreciation)	6,297	7,556
Research and development	36,830	17,793
Selling, general and administrative	98,970	74,191
Gain in fair value of contingent consideration	(1,412)	(162)
Intangible asset amortization	1,589	1,572
Total operating expenses	142,274	100,950
Loss from operations	(67,275)	(6,374)
Interest expense, net	(1,082)	(2,264)
Loss before income taxes	(68,357)	(8,638)
Income tax expense	0	(2,580)
Net loss	$ (68,357)	$ (11,218)
Net loss per common share, basic	$ (1.44)	$ (0.26)
Net loss per common share, diluted	$ (1.44)	$ (0.26)
Weighted average common shares outstanding, basic	47,393,563	43,523,631
Weighted average common shares outstanding, diluted	47,393,563	43,523,631
Product Sales
Revenues [Abstract]
Revenue	$ 74,096	$ 28,569
License Revenue
Revenues [Abstract]
Revenue		65,735
Royalty Revenue
Revenues [Abstract]
Revenue	$ 903	$ 272

AXSM Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 331,441	$ 386,193
Accounts receivables, net	101,434	94,820
Inventories, net	15,583	15,135
Prepaid and other current assets	12,032	8,115
Total current assets	460,490	504,263
Equipment, net	812	846
Right-of-use asset - operating lease	6,411	6,772
Goodwill	12,042	12,042
Intangible asset, net	51,697	53,286
Non-current inventory and other assets	14,276	11,027
Total assets	545,728	588,236
Current liabilities:
Accounts payable	53,791	40,679
Accrued expenses and other current liabilities	82,716	90,501
Operating lease liability, current portion	1,153	1,267
Contingent consideration, current	6,388	6,407
Total current liabilities	144,048	138,854
Contingent consideration, non-current	70,000	73,300
Loan payable, long-term	178,689	178,070
Operating lease liability, long-term	7,258	7,035
Finance lease liability, long-term	1,697
Total liabilities	401,692	397,259
Stockholders’ equity:
Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding)
Common stock, $0.0001 par value per share (150,000,000 shares authorized, 47,464,575 and 47,351,363 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively)	5	5
Additional paid-in capital	1,047,959	1,026,543
Accumulated deficit	(903,928)	(835,571)
Total stockholders’ equity	144,036	190,977
Total liabilities and stockholders’ equity	$ 545,728	$ 588,236

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

CEO	Dr. Herriot Tabuteau M.D.
WEBSITE	axsome.com
INDUSTRY	Biotechnology
EMPLOYEES	422

Axsome Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Axsome Therapeutics Inc? What does AXSM stand for in stocks?

AXSM is the stock ticker symbol of Axsome Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Axsome Therapeutics Inc (AXSM)?

As of Fri May 17 2024, market cap of Axsome Therapeutics Inc is 3.64 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers.

What is the fair value of AXSM stock?

You can check AXSM's fair value in chart for subscribers. The fair value of Axsome Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Axsome Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AXSM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Axsome Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AXSM is over valued or under valued. Whether Axsome Therapeutics Inc is cheap or expensive depends on the assumptions which impact Axsome Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXSM.

What is Axsome Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, AXSM's PE ratio (Price to Earnings) is -12.28 and Price to Sales (PS) ratio is 14.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXSM PE ratio will change depending on the future growth rate expectations of investors.